David M. Tanen - 20 Jun 2025 Form 4 Insider Report for Kronos Bio, Inc. (KRON)

Reporting relationship
Director
Issuer ticker
KRON
Reported as of
20 Jun 2025
Net transaction value
-$520,856
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
20 Jun 2025, 16:15:27 UTC
Prior SEC filing
26 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ David M.Tanen

Key filing fact

David M. Tanen filed Form 4 for Kronos Bio, Inc. (KRON) on 20 Jun 2025.

Key facts

  • This page summarizes David M. Tanen's Form 4 filing for Kronos Bio, Inc. (KRON).
  • 11 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 20 Jun 2025, 16:15.

Change

  • Previous filing in this sequence was filed on 26 Jun 2024.
  • Current net transaction value: -$520,856.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001170542 Primary reporting owner

TANEN DAVID M

Relationship
Director
Address
C/O KRONOS BIO, INC., 301 BINNEY STREET, 2ND FLOOR EAST, CAMBRIDGE
Signature
/s/ David M.Tanen
Signature date
20 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KRON transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$207,154
Shares
-363,428
Change %
-100%
Price
$0.5700
Shares after
0
Date
20 Jun 2025
Ownership
Direct
Footnotes
F1, F2
KRON transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$268,601
Shares
-471,230
Change %
-100%
Price
$0.5700
Shares after
0
Date
20 Jun 2025
Ownership
See Footnote
Footnotes
F1, F2, F3
KRON transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$15,034
Shares
-26,375
Change %
-100%
Price
$0.5700
Shares after
0
Date
20 Jun 2025
Ownership
By Son
Footnotes
F1, F2
KRON transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$15,034
Shares
-26,375
Change %
-100%
Price
$0.5700
Shares after
0
Date
20 Jun 2025
Ownership
By Son
Footnotes
F1, F2
KRON transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$15,034
Shares
-26,375
Change %
-100%
Price
$0.5700
Shares after
0
Date
20 Jun 2025
Ownership
By Daughter
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$0
Shares
-85,608
Change %
-100%
Price
$0.000000
Shares after
0
Date
20 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
85,608
Exercise price
$4.14
Footnotes
F4
KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$0
Shares
-19,892
Change %
-100%
Price
$0.000000
Shares after
0
Date
20 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
19,892
Exercise price
$4.14
Footnotes
F4
KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$0
Shares
-20,600
Change %
-100%
Price
$0.000000
Shares after
0
Date
20 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,600
Exercise price
$24.18
Footnotes
F4
KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$0
Shares
-34,000
Change %
-100%
Price
$0.000000
Shares after
0
Date
20 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
34,000
Exercise price
$3.53
Footnotes
F4
KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$0
Shares
-34,000
Change %
-100%
Price
$0.000000
Shares after
0
Date
20 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
34,000
Exercise price
$1.48
Footnotes
F4
KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$0
Shares
-34,000
Change %
-100%
Price
$0.000000
Shares after
0
Date
20 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
34,000
Exercise price
$0.9500
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David M. Tanen is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

Footnote F2

[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

Footnote F3

By the David Tanen Revocable Grantor Trust.

Footnote F4

As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .